On February 9, 2026 IN8bio (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ ) T cell therapies and T cell engagers for cancer and autoimmune diseases, reported the promotion of Kate Rochlin, Ph.D., to President and Chief Operating Officer, effective immediately.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Rochlin has served as IN8bio’s Chief Operating Officer since December 2021, following her tenure as Vice President and Associate Vice President of Operations and Innovation beginning in August 2020. In her expanded role, she will continue to oversee company operations as IN8bio advances its clinical and preclinical pipeline and prepares for its next phase of growth.
"Kate has been instrumental in translating IN8bio’s strategy into disciplined execution," said William Ho, Chief Executive Officer and Co-Founder of IN8bio. "Through her leadership and ability to align teams across operations, manufacturing, clinical, and research, she has played a central role in advancing our clinical programs, and T cell engager platform and delivering critical milestones on schedule. I am confident that her promotion to President will further strengthen the organization."
Dr. Rochlin brings more than 17 years of experience across biotechnology company development, including scientific research, intellectual property, business development, clinical manufacturing and operations spanning corporate strategy, partnering, and team buildout. Prior to joining IN8bio, she was Chief Business Officer at Curadigm, a biotech developing precision-targeted drug delivery technologies, where she helped lead the company’s spin-out from Nanobiotix.
Since joining IN8bio, Dr. Rochlin has played a key role in advancing the company’s programs, including INB-619, a potential first-in-class, pan-γδ T cell engager for deep B cell depletion in autoimmune disease. IN8bio recently presented preclinical data showing that INB-619 achieved complete B cell depletion comparable to approved T cell engagers, with minimal adverse cytokine release and robust expansion of γδ T cells. These results validate the differentiation of IN8bio’s T cell engager platform and support continued regulatory engagement and advancement toward the clinic. Dr. Rochlin has also been instrumental in developing and expanding IN8bio’s clinical manufacturing program, leading analytical, quality, regulatory and GMP manufacturing teams across multiple Phase 1 and 2 clinical programs in glioblastoma and hematological cancers.
"I’m honored to take on this expanded role and broader leadership responsibilities at such an important time for IN8bio," said Dr. Rochlin. "With encouraging clinical data emerging from our γδ T cell therapy programs and novel gamma-delta T cell engager technology, we are well positioned to build on this momentum. I look forward to continuing to work closely with our team to execute on our corporate priorities and position IN8bio for long-term success."
Dr. Rochlin earned a Ph.D. in Molecular Biology and Genetics from Weill Cornell Medical College, conducted research at Sloan Kettering Institute, and earned a BA in Biology from the University of Pennsylvania.
(Press release, In8bio, FEB 9, 2026, View Source [SID1234662545])